VPT:CC - Ventripoint Diagnostics Makes Significant Sale to the Largest Heart Center in Germany
(TheNewswire)
Toronto, O N -TheNewswire - July 5, 2023 - VentripointDiagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ( OTC:VPTDF) is pleased to announce that a VMS+ product has been purchasedby and is fully operstional in the Deutsches Herzzentrum der Charité (DHZC), German Heart Center, in Berlin, Germany.
Prof. Felix Berger, Director of the Clinic forCongenital Heart Disease – Pediatric Cardiology at DHZC stated,"VMS+ not only gives us a very precise spatial view of complexcongenital malformations at any time, but it also provides us withimportant data on the function of the heart muscle. This allows us toplan therapy even more precisely, check it at any time and adjust itif necessary.”
The DHZC is the university heart center of Charité– UniversitätsmedizinBerlin which is the largest heart center inGermany for the treatment of all cardiovascular diseases in patientsof all ages. The Charité is one of Germany’s mostresearch-intensive medical institutions and was ranked this year asthe 7 th best hospital in the world and the best in Europe byNewsweek(https://www.newsweek.com/rankings/worlds-best-hospitals-2023). TheDHZC’s departments for Congenital Heart Disease – PediatricCardiology and Congenital and Pediatric Heart Surgery are among theleading institutions in Europe for the diagnosis and therapy ofcongenital and acquired heart disease (CHD). In 2021, the unit treated1,005 statutory and 2,300 ambulatory CHD children. These numbers arecontinuously growing with the patients coming from Eastern Europe andneighbouring countries. Approximately 6,000 children are born inGermany every year with heart defects that require treatment andlifelong monitoring. The German Heart center is the central point ofcontact for advice, diagnostics, and therapy for the life of patientswith CHD.
The VMS+ will be an asset to the hospital’s pediatriccardiology led by Prof. Dr. med. Felix Berger, a world-renownedpediatric cardiologist. The innovative product was purchased in orderto improve efficacy and patient management in the CHD department. TheVMS+ offers an accessible and timely cardiac diagnostic alternative tocMRI. The VMS+ with Knowledge-Based Reconstruction (KBR™) producesmetrics that are more accurate and reliable compared to other standardultrasound measurement techniques. This exciting new site will givethe VMS+ larger visibility in the European market. Ventripoint strivesto advance care for cardiovascular diseases for everyone andespecially for children.
The DHZC’s purchase was enabled by Ventripoint’spartner in Europe, Angiopro GmbH, a leading German-baseddistributor.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in themanagement of their patients. Providing better care to patients servesas a springboard and basic standard for all of Ventripoint's productsthat guide our future developments. In addition, VMS+ is versatile andcan be used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe and Canada.
www.ventripoint.com
For further information, pleasecontact:
Jonathan Robinson CFA
(416) 669-1001
About the German Heart Center Berlin
As of January 1, 2023, Charité - UniversitätsmedizinBerlin and Deutsches Herzzentrum Berlin - Stiftung des bürgerlichenRechts (DHZB) merge their cardiac medical facilities to form DeutschesHerzzentrum der Charité (DHZC). The DHZC islocated at the three clinical campuses of Charité at CampusVirchow-Klinikum, Campus Charité Mitte and Campus Benjamin Franklin.It comprises a total of eight clinics and institutes with about 2,500employees and has about 470 beds. This formation creates one of thelargest cardiac centers in Germany for the treatment of allcardiovascular diseases in patients of all ages. Website:https://www.dhzb.de
About Angiopro GmbH
Angiopro is a classic distributor company withheadquarters in Speyer, Rhineland-Palatinate. The company portfolioincludes the distribution of vascular medical devices as well as theworld's leading software in patient screening before and aftercardiovascular interventions. Website: www.angiopro.de
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information or statements. Theforward-looking statements and information are based on certain keyexpectations and assumptions made by the Company. Although the Companybelieves that the expectations and assumptions on which suchforward-looking statements and information are based are reasonable,undue reliance should not be placed on the forward-looking statementsand information because the Company can give no assurance that theywill prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2023 TheNewswire - All rights reserved.